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and we show for different scenarios how close the estimates come. For selected 
treatment comparisons we present effect-sizes with confidence intervals. We apply 
also the Bayesian extension and discuss its advantages. ConClusions: Based on 
our research we give recommendations of when the Lumley-method should be best 
applied, and discuss limitations.1 Lumley T: Network meta-analysis for indirect 
treatment comparisons. Stat. Med. 2002; 21: 2313-2324.
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AnAlysis of VoluMe And stRuctuRe of oRAl AntidiAbetic dRugs 
consuMPtion in ukRAine
Iakovlieva L., Kyrychenko O., Gerasymovà O., Kuznetsov I.
National University of Pharmacy, Kharkiv, Ukraine
objeCtives: Evaluation and comparison of oral antidiabetic drugs (OAD) consump-
tion at state level are an important element at control of 2ndtype DM patients treat-
ment quality. The objective of the study is to determine the volumes and structure 
of OAD consumption in Ukraine and to compare it with consumption in the other 
countries. Methods: ATC/DDD-methodology with application of DDD/1000/day 
(DID). The evaluation is based on consumption volume, provided by “PharmXplorer/
Pharmstandard” analytical system of market research. Results: In year 2008, OAD 
consumption in Ukraine was 5.78 DID and increased to 11.13 DID in year 2013. In 
year 2011, OAD consumption was 54.28 DID in France, 44.58 - in Germany (S. Pichetti, 
C. Sermet, S. van der Erf, 2013), 33.25 - in Estonia, 29.87 - in Latvia (Baltic Statistics 
on Medicines 2010–2012), showing that OAD consumption in Ukraine was very low. 
Structure of OAD consumption in Ukraine shows that 98.95% of the total consump-
tion volume is distributed to 2 groups: sulfonylureas (73.84%) and biguanides (25%) 
and only 1,05% to gliptines, glitazones, glucosidases and glinides. The total share 
of preparations of sulfonylureas and biguanides group in the total consumption 
structure in France and Germany was 71.8% and 80.1% respectively of the total 
consumption OAD. In year 2013, OAD of the II generation - gliclazide (3.01 DID) and 
glibenclamide (2,09 DID) had the highest consumption level in sulfonylureas group, 
preparations of III generation - glimepiride (2,09 DID) had lesser consumption rate. 
Out of 61 OAD trade names (TN), presented in the pharmaceutical market of Ukraine, 
8 TNs took 89.78% of the total consumption volume. ConClusions: Very low rate 
of OAD consumption in Ukraine shows the necessity of its increase. Analysis of OAD 
consumption structure evidences the application of relatively cheap and long-used 
medical preparations for treatment of 2nd type DM, which is largely due to financial 
capacities of payers.
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objeCtives: In the context of uncertainty due to the lack of sound data, expert 
opinion is considered as a legitimate source of information for decision-makers. 
The use of experts’ opinion requires to quantifying their uncertainty about a specific 
event by eliciting a probability distribution of the event. The objectives of this study 
were to develop a web-based tool enabling users to remotely elicit the opinion of a 
group of geographically dispersed experts and to evaluate the measurement prop-
erties of this tool. Methods: The web-based tool allowed first to elicit univariate 
probability distributions separately from each expert and secondly to calculate an 
aggregated distribution. The elicitation method was the four-interval method that 
was judged to be more appropriate for non-statistician experts due to its clarity 
of use. As recommended to limit biases, the elicitation questionnaire included a 
training exercise and a graphical feedback so that the experts could validate their 
distributions. A pilot survey was conducted among all the French regional medical 
device vigilance correspondents (n= 24) about the risk of failure (%) of an implantable 
medical device. Results: Twenty-two correspondents (92%) completed the survey. 
An aggregated distribution was calculated from the elicited individual distributions 
and a beta distribution was fitted reflecting the group uncertainty about the risk of 
failure. Feasibility was judged in view of the users’ feedback and time to completion. 
Validity and reliability were assessed using data on comprehensiveness, internal 
coherence and test-retest reliability. ConClusions: The proposed web-based tool 
was feasible, valid and reliable. It should be useful in making expert elicitation 
easier and more practical.
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objeCtives: The main objective of the study is to promote awareness and assess 
the knowledge of adolescents on medication use, importance of balanced diet and 
physical activity. Methods: The study was conducted among the adolescents 
aged from16-18 years in Regions of Guntur. The volunteers are allowed to fill their 
informed consent to be a part of the study. The questionnaire was distributed to all 
the volunteers included in the study, which includes questions on their medica-
tion taking behaviour, dietary habits and physical activity. The response was then 
analyzed to assess the knowledge on medication use, balanced diet and physical 
activity. Results: Among the 165 individuals on assessment of their medication 
taking behavior78% of them do not follow their prescription, 61% of the individuals 
do not have any idea on their medication use and a majority of 74% are not aware 
of the unwanted effects caused by the medication. On assessment of their dietary 
habits and physical activity, 62% of the individuals include meal rich in fat, 42% 
of the individuals skip their breakfast every day and 41% of them will not include 
leafy vegetables as part of their regular meal. 65% of individuals do not perform a 
regular physical activity ConClusions: It is the responsibility of the pharmacist 
in a user-friendly environment during a decision-making setting avoiding disad-
vantages of pre-prepared analyses.
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An eVAluAtion And coMPARison of Methods used in suRViVAl 
AnAlysis to fit distRibutionAl cuRVes to kAPlAn-MeieR dAtA
Haines P.
Curo, Marlow, UK
objeCtives: HTA bodies increasingly require accurate survival estimates in order to 
provide reliable recommendations. It is argued that access to individual patient data 
(IPD) can improve their accuracy. This paper aims to assess to what degree extract-
ing IPD from published Kaplan-Meier curves helps improve extrapolated survival 
estimates. Some methods currently used for HTA submissions fit a survival curve 
directly to a published Kaplan-Meier curve, but does this lack accuracy? Methods: 
Two methods used to extract the IPD from Kaplan-Meier curves reviewed in this 
paper are by Guyot et al (Guyot, Ades, Ouwens, & Welton, 2012) and Hoyle and 
Henley (Hoyle & Henley, 2011) which were compared against the outcomes of the 
standard ‘least squares’ method. Comparisons were made for two situations: 1) 
when numbers at risk are available at different time points throughout the Kaplan-
Meier curve and 2) when numbers at risk are only available at the start. Results: 
The three methods resulted in the long-normal distribution showing the best fit, 
with all containing the true mean and median within their confidence intervals. 
However, the Hoyle and Henley method estimates a mean marginally closer to the 
true mean than the other methods in both situations. When many numbers at risk 
are provided, the Hoyle and Henley method gives narrower confidence intervals. 
Both extraction methods slightly outperformed the least squares method. The three 
methods give median estimates and resulting confidence intervals which are statis-
tically equivalent to that of the IPD, except for the Guyot method when numbers at 
risk are not available. ConClusions: In conclusion, extraction methods can give 
marginally better results than the Least Squares method. However, these results 
may not be applicable to other examples. In addition, the extra time taken to run 
extraction methods could be too large to account for the small improvement in 
accuracy of results.
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objeCtives: A frequent challenge in Network Meta-Analysis (NMA) arises from the 
fact that several interventions may belong to the same class and be given at multiple 
doses. Models have been proposed for NMA accounting for dose-response, but these 
models do not also consider class effects at the same time, which are important 
from a decision making perspective. We aim to develop a framework that extends 
dose-response NMA methods to account for dose and class effects simultaneously, 
and explore the ability of these models to explain heterogeneity, improve model fit 
and increase precision of the estimated treatment effects. Methods: Using clini-
cal trial data of treatments for acute migraine obtained from Cochrane reviews, we 
developed multi-level NMA models to simultaneously account for dose-response 
and class-effects, in particular defining a ‘dose’, ‘treatment’ and ‘class’ hierarchy 
within the NMA models. We explored a non-parametric “random walk” model con-
strained to be monotonically increasing with dose. Multi-level NMA models were 
compared to 1-level (standard) NMA models where interventions were ‘lumped’ at 
each level separately. Results: The model that explicitly included monotonic dose-
response and class effects showed the best fit and least heterogeneity, and produced 
more precise measures of treatment effect than all 1-level models. NMA models that 
made less plausible assumptions around dose-response had poorer fit than models 
with monotonic dose-response. ConClusions: We have developed a framework 
for simultaneously estimating treatment effects at the ‘dose’, ‘treatment’ and class 
level within the same NMA model. The framework can help decision makers iden-
tify the most appropriate class, drug, and dose, however, results of dose-response 
models are not straightforward to interpret or implement from a decision making 
perspective. Careful consideration should be given to dose-response and similarity 
of interventions when conducting NMA.
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the luMley-Method, A RecoMMended netWoRk MetA-AnAlysis foR 
indiRect coMPARisons, suMMARized foR PRActitioneRs
Petto H.1, Kadziola Z.1, Belger M.A.2
1Eli Lilly Regional Operations GmbH, Vienna, Austria, 2Eli Lilly and Company, Windlesham, UK
objeCtives: In recent years we have seen a growth in the use of network meta-
analysis as part of the evidence base for Health Technology Assessments, with the 
Lumley method, published in 20021being a key reference when considering both 
indirect and direct comparisons. Unfortunately the program-code included in the 
manuscript cannot easily be run, and the given examples cannot be replicated, 
even with corrected code. To give practitioners helpful insight into the method, 
we start from individual patient data of head to head trials and show how from 
subsequent data-aggregation the Lumley-model (a random-effects model) can be 
derived. Methods: We give more details than in the article of how the proposed 
variance function aggregates study-heterogeneities and of how effect-sizes and 
confidence intervals can be derived from the parameter- and variance-estimates. 
We discuss why dependencies coming from the network-structure should be incor-
porated into confidence-interval calculations and of how the model can be extended 
with an in the article suggested Bayesian approach for modeling the random-effects 
parameters. Results: We include an example of how the Lumley-method can be 
applied in practice. We present based on the program-example in the article a cor-
rected R-version and a translation into SAS. For both we show how aggregated 
study-data should be structured and dummy-coded before running the program. 
The Lumley-method was applied to simulated data with known model-parameters 
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or to refine the decision formulation if uncertainty is high, potentially leading to 
improved decision-making.
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Methods used in Published studies to indiRectly coMPARe noVel 
AnticoAgulAnts (noAcs) With WARfARin foR the PReVention of 
stRoke in PAtients With AtRiAl fibRillAtion (Af)
Daacke I.M.
Boehringer Ingelheim UK, Bracknell, UK
intRoduCtion: The three main novel anticoagulants (NOACs) currently licensed 
in Europe, apixaban, dabigatran and rivaroxaban, have all been directly compared 
against warfarin in randomised controlled trials. However, none of the three drugs 
have been directly compared against each other. Thus, there has been an increase 
in the number of meta-analyses and indirect comparisons published comparing 
the relative efficacy and safety of these novel anticoagulants against each other 
via warfarin as a common comparator. objeCtives: Systematically review all 
meta-analyses and indirect comparisons evaluating the NOACs against warfarin 
for the prevention of stroke in patients with AF and critically appraise the statistical 
methods used to do so. Methods: Systematic searches of EMBASE, MedLine, EBM 
Reviews, EconLIT as well as manual searches of ClincalTrials. gov, the Cochrane 
Library, CADTH, NICE, NHSEED and HTA were conducted. Data was abstracted from 
any citation applying statistical methods to compare the efficacy and safety of 
NOACs for the prevention of AF-related stroke. Information regarding the statistical 
approach; model assumptions; data presentation; interpretation of the evidence; 
and discussions of internal and external validity was used to quality rate each 
study. Results: Bucher’s method of adjusted indirect comparison was most widely 
used. There were generally three main model assumptions required: the similarity, 
homogeneity and consistency assumptions, each being investigated with varying 
scrutiny in the studies reviewed. According to the quality assessment, the indirect 
comparison conducted by Wells and colleagues (2012) is of the highest relative qual-
ity. ConClusions: The limited number of RCTs available comparing the NOACs to 
standard therapy, creates considerable uncertainty surrounding the comparative 
efficacy and safety of these anticoagulants. In order to establish which individual 
NOAC is most likely to benefit a given patient population, indirect comparisons and 
meta-analyses are increasingly used. However, the quality of indirect comparison 
studies are variable and results should be interpreted with care.
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objeCtives: Matching-adjusted indirect comparison (MAIC) is a novel comparative 
effectiveness approach to address biases that can appear in traditional indirect 
comparison (IC) methods when patient characteristics differ across trials. We exam-
ined three unanswered MAIC methodological questions and applied the proposed 
solutions to a comparison of ADHD treatments. Methods: Using individual patient 
data from two randomized controlled trials (RCTs) comparing guanfacine (GXR) 
vs placebo and published summary statistics from four RCTs comparing atomox-
etine (ATX) vs placebo, MAIC was used to reweight the GXR data so that observable 
GXR patient characteristics matched those of ATX patients. Change in ADHD-RS-IV 
scores was the primary endpoint. Comparative efficacy results were evaluated for 
their sensitivity to changes in the following three MAIC specifications: variable 
selection using regression-based methods, statistical moments matched (i.e., mean 
vs mean and variance), and matching on placebo-arm outcomes. Results: Both 
treatments decreased ADHD-RS-IV scores relative to placebo (-17.9 GXR vs -10.7 
placebo; -14.6 ATX vs -5.8 placebo). In the baseline MAIC specification adjusting for 
patient baseline characteristics and placebo arm outcomes, GXR produced larger 
decreases in ADHD-RS-IV scores than ATX (Δ : -3.9, p< 0.004). The results were insen-
sitive to adding variables to the matching algorithm (Δ : -3.8, p< 0.023), or match-
ing only covariate means rather than both means and variances (Δ : -3.6, p< 0.006). 
Applying MAIC without matching placebo arm outcomes indicated a slightly greater 
decrease in ADHD-RS-IV scores for ATX, but there was no statistically significant 
difference between GXR and ATX (Δ : 0.6, p< 0.649). ConClusions: In this study, 
MAIC results were insensitive to variable selection via regression and the statistical 
moments matched, but matching the placebo arms altered the results. Matching 
placebo arm outcomes is valid when unobserved trial-specific factors have a dif-
ferential impact on a trial’s treatment and control arm outcomes; this was likely 
the case in this GXR-ATX study.
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PRoPosed checklist foR non-stAtisticiAns to Assess the QuAlity of A 
netWoRk MetA-AnAlysis in the context of A nice subMission
Pacou M.1, Gauthier A.2, Taieb V.2, Bec M.2, Belhadi D.2, Guillemot J.2
1Amaris, Paris, France, 2Amaris, London, UK
objeCtives: To develop a checklist to assess the quality of a network meta-analysis 
(NMA) in the context of a submission to NICE. This checklist is intended to be com-
prehensible and easy-to-use by non-statisticians to assess whether an NMA is suit-
able for a submission to NICE and/or to populate cost-effectiveness models within 
the context of the NICE requirements. Methods: An ad-hoc search of the literature 
was conducted to identify existing checklists. Items from these checklists were 
extracted and critically reviewed. Recommendations from NICE as well as existing 
NICE submissions and corresponding comments from the evidence review groups 
(ERG) were used to develop the checklist. Our checklist was validated by health 
economists and pharmacists not trained in NMA on the basis of a NICE submission 
to promote awareness on the medications, balanced diet and physical activity to 
improve the quality of life of an individual.
PRM202
siMulAting indiViduAl PAtient leVel dAtA to AddRess tReAtMent 
sWitching When only suMMARy dAtA ARe AVAilAble
Boucher R., Abrams K., Lambert P.C.
University of Leicester, Leicester, UK
objeCtives: Treatment switching commonly occurs in the pivotal HTA evidence 
for advanced or metastatic cancer treatments submitted to reimbursement agen-
cies. Simple approaches, such as Intention-to-treat (ITT) analysis, have typically 
been used to analyse data with treatment switching, despite simulation studies 
showing these to drastically underestimate the underlying treatment effect. With 
more manufacturers conducting indirect comparisons (ICs) to compare treatments, 
summary data are being used more in analysis. The method outlined addresses 
treatment switching when only summary data are available to ensure appropri-
ate estimates for the treatment effect are achieved when the data is then used 
in an IC. Methods: Using digitised survival curves, multiple datasets that are 
representative of the original individual patient data (IPD) are simulated. Treatment 
switching information is estimated from reported information on progression-free 
survival, and then established methods which adjust appropriately for treatment 
switching used to analyse the simulated data. This approach is applied to an exam-
ple from a technology appraisal (TA) submitted to National Institute for Health and 
Care Excellence (NICE), and the ITT hazard ratio and median survival obtained and 
compared with those reported, before analysis using a Rank Preserving Structural 
Failure Time Model (RPSFTM). Results: Averaging over 2000 datasets, the replicated 
summary statistics were similar to those reported. Both median survival times were 
within 1 month of those stated in the TA and the hazard ratio less than 0.05 differ-
ent. Subsequent analysis using an RPSFTM shows the new treatment to be more 
effective, and inappropriately adjusting for crossover to have underestimated the 
treatment effect. ConClusions: Adjusting summary data is important as other-
wise, subsequent analysis conducted will give inappropriate results. The simulated 
data approach well represents the original IPD, giving on average similar results to 
those reported. Hence, the further analysis to address treatment switching issues 
gives more appropriate treatment effect estimates.
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Modeling the effect of coMbining AlogliPtin With duAl theRAPy in 
tyPe 2 diAbetes
Johnson K.I.1, Palin H.J.1, Sibbring G.C.1, Selby R.2
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objeCtives: To estimate the impact of combining the dipeptidyl peptidase-4 (DPP-
4) inhibitor, alogliptin, with metformin and sulfonylurea (alogliptin triple therapy) 
to achieve glycemic control in patients with type 2 diabetes. Methods: Since no 
clinical trial of alogliptin triple therapy has been conducted, the effect of adding 
alogliptin to dual therapy (metformin+sulfonylurea) was modeled using novel addi-
tive effect methodology, utilizing data from a previous mixed treatment comparison 
(MTC). The following assumptions were made: the efficacy of triple therapy can be 
estimated as a function of its constituent parts, and the efficacies of the constituent 
parts are equivalent. Pooled data for the absolute change from baseline in glyco-
sylated hemoglobin (HbA1c) from trials of sitagliptin, linagliptin, and vildagliptin 
triple therapy, and for their constituent parts, informed the model. A weighting fac-
tor, β coefficient, derived from DPP-4 mono, dual, and triple therapy trials, was used 
to estimate the effect size for triple therapy using the sum of the constituent parts. 
The estimated mean β value was validated against the observed effect size of alog
liptin+pioglitazone+metformin, using the pooled effect from the MTC. Results: 
An estimated mean β coefficient value of 0.83 represented the DPP-4 inhibitor class. 
Validation of the approach resulted in a similar β coefficient for pioglitazone triple 
therapy (0.82). Absolute change in HbA1c from baseline for alogliptin triple therapy 
was estimated as -0.77% (95% CI -1.16, -0.39). Similar values were observed in the 
MTC for sitagliptin -0.94% (95% CI -7.34,5. 40), linagliptin -0.65 (95% CI -6.87,5. 60), 
and vildagliptin -0.80% (95% CI -7.00,5. 43). ConClusions: The wide confidence 
interval is consistent with expectations in the literature and is a limitation of the 
method employed, in that it requires the variance of the individual studies to be 
summated. Nevertheless, the method demonstrates the value of modeling when 
clinical trial evidence is not available.
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unceRtAinty And PRobAbilistic Methods in Multi-cRiteRiA decision 
AnAlysis
O Meachair S., Walsh C.
Trinity College Dublin, Dublin, Ireland
objeCtives: Multi-Criteria Decision Analysis (MCDA) is a collection of techniques 
for choosing optimal decisions when two or more criteria need to be taken into 
account in the decision process. Most MCDA techniques require the specification 
of a number of parameters; criteria weights, utility functions or indifference thresh-
olds. We wish to account for the uncertainty in these parameters which may arise 
due to the fuzzy nature of the Decision Maker’s preferences, conflicting opinions 
between a group of decision makers or population group, or the abstract nature of 
the parameters. Methods: We implement some MCDA models from a Bayesian 
perspective where parameters come from posterior probability distributions repre-
senting the combination of available knowledge on the parameters. Such knowledge 
can come from empirical data, expert elicitation, survey data, decision-making com-
mittees, or some combination of these. Results: Depending on the method used, 
the end result is either a benefit function which quantifies the uncertainty in the 
benefit score for each action, or a rankogram which depicts the uncertainty in the 
ranking of actions. ConClusions: Knowledge about this uncertainty allows deci-
sion makers to make more informed decisions. A decision action may be clear when 
uncertainty is sufficiently low, or it may be necessary to request more information 
